Celgene Corp /de/ (CELG): Ernest Mario , director of Celgene Corp /de/ sold 15,000 shares on Sep 23, 2016. The Insider selling transaction was reported by the company on Sep 26, 2016 to the Securities and Exchange Commission. The shares were sold at $109.42 per share for a total value of $1,641,300.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 26, 2016, Richard W Barker (director) sold 20,000 shares at $110.82 per share price.On Sep 16, 2016, Gilla Kaplan (director) sold 9,710 shares at $106.44 per share price.Also, On Aug 24, 2016, James J Loughlin (director) sold 27,500 shares at $114.10 per share price.On Aug 23, 2016, Michael D Casey (director) sold 43,134 shares at $114.01 per share price.
Celgene Corporation: On Thursday, Sep 22, 2016 heightened volatility was witnessed in Celgene Corporation which led to swings in the share price. The shares opened for trading at $110 and hit $110.85 on the upside , eventually ending the session at $110.57, with a gain of 0.90% or 0.99 points. The heightened volatility saw the trading volume jump to 44,58,373 shares. The 52-week high of the share price is $128.39 and the company has a market cap of $85,704 M . The 52-week low of the share price is at $93.05.
Company has been under the radar of several Street Analysts.Celgene Corporation is Initiated by Stifel to Buy and the brokerage firm has set the Price Target at $138. The Rating was issued on Jul 15, 2016.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.